Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 5:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 270 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Herpes Simplex Virus Infection Clear all
Completed Phase 3 Interventional

Herpetic Eye Disease Study (HEDS) II

NCT00000139
View directory record Official record
Conditions
Keratitis, Herpetic, Ocular Herpes Simplex, Herpes Simplex
Interventions
Stress, Acyclovir
Behavioral · Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
8
States / cities
San Francisco, California • Atlanta, Georgia • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2010 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

Vitamin D Supplementation And Varicella Zoster Virus Vaccine Responsiveness In Older Long-Term Care Residents

NCT01262300
View directory record Official record
Conditions
Immunosenescence, Shingles
Interventions
Varicella Zoster Virus Vaccine (Zostavax)
Biological
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years and older
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate GSK Biologicals' Herpes Zoster Vaccine GSK1437173A in Human Immunodeficiency Virus (HIV)-Infected Subjects

NCT01165203
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
123 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
5
States / cities
Long Beach, California • San Francisco, California • Orlando, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 30, 2018 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 2 Interventional

Dextromethorphan Versus Placebo for Neuropathic Pain

NCT00001344
View directory record Official record
Conditions
Diabetic Neuropathies, Herpes Zoster, Neuralgia
Interventions
dextromethorphan
Drug
Lead sponsor
National Institute of Dental and Craniofacial Research (NIDCR)
NIH
Eligibility
Not listed
Enrollment
129 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

Acyclovir in Preventing Herpes Simplex Virus Infection in Patients With Neutropenia

NCT00855309
View directory record Official record
Conditions
Herpes Simplex
Interventions
acyclovir sodium
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Cross-vaccination Study of GSK Biologicals' Herpes Zoster Subunit (HZ/su) Vaccine (GSK 1437173A) in Subjects Who Previously Received Placebo in ZOSTER-006 (NCT01165177) and ZOSTER-022 (NCT01165229) Studies.

NCT02690207
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
8,687 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2019
U.S. locations
37
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Mar 4, 2021 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 2 Interventional Results available

Trial on Efficacy and Safety of Pritelivir Ointment for Treatment of Labial Herpes

NCT02871492
View directory record Official record
Conditions
Herpes Labialis
Interventions
Pritelivir 5% w/w ointment, Pritelivir ointment matching placebo, Zovirax® cream
Drug
Lead sponsor
AiCuris Anti-infective Cures AG
Industry
Eligibility
18 Years and older
Enrollment
362 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
10
States / cities
Scottsdale, Arizona • Santa Rosa, California • Pinellas Park, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Jul 13, 2021 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

Acyclovir Herpes Simplex Virus (HSV) Skin, Eye, and Mouth

NCT00031447
View directory record Official record
Conditions
Herpes Simplex
Interventions
Acyclovir, Placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Up to 28 Days
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Little Rock, Arkansas • San Diego, California + 24 more
Source: ClinicalTrials.gov public record
Updated May 16, 2012 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 2 Interventional

Pilot Study of High-Dose Capsaicin Patches to Treat Postherpetic Neuralgia Pain

NCT00034710
View directory record Official record
Conditions
Neuralgia, Pain, Peripheral Nervous System Diseases, Herpes Zoster
Interventions
Capsaicin Patch
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002
U.S. locations
8
States / cities
Phoenix, Arizona • Tucson, Arizona • Naples, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2006 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 2 Interventional

Study of NGX-1998 for the Treatment of Postherpetic Neuralgia

NCT01228838
View directory record Official record
Conditions
Postherpetic Neuralgia, Pain
Interventions
NGX-1998, Placebo Liquid
Drug
Lead sponsor
NeurogesX
Industry
Eligibility
18 Years to 90 Years
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
35
States / cities
Huntsville, Alabama • Tucson, Arizona • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 10, 2012 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Consistency, Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults ≥ 50 Years of Age

NCT02075515
View directory record Official record
Conditions
Herpes Zoster, Herpes Zoster Vaccine
Interventions
Herpes Zoster vaccine (GSK 1437173A)
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
651 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
3
States / cities
Mesa, Arizona • Wichita, Kansas • Milford, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 14, 2021 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 1Phase 2 Interventional

Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative Persons

NCT05683834
View directory record Official record
Conditions
Epstein-Barr Virus Infection, Infectious Mononucleosis, Herpesvirus
Interventions
Matrix-M1 Adjuvant, EBV gp350-Ferritin Vaccine, Placebo Comparator
Drug · Other
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 25 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
2
States / cities
Bethesda, Maryland • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2026 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

Trial Evaluating Safety, Tolerability and Immune Response of AG-707

NCT00231049
View directory record Official record
Conditions
Genital Herpes
Interventions
AG-707
Drug
Lead sponsor
Agenus Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
3
States / cities
Indianapolis, Indiana • Portland, Oregon • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Oct 27, 2008 · Synced Oct 5, 2026, 5:01 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Study on the Reactogenicity, Safety and Immune Response of a Vaccine Against Herpes Simplex Virus (HSV)-2 in Healthy Participants Aged 18-40 Years

NCT04762511
View directory record Official record
Conditions
Herpes Simplex
Interventions
Lower dose formulation of HSV vaccine (GSK4108771A), Low dose formulation of HSV vaccine (GSK4108771A), Medium dose formulation of HSV vaccine (GSK4108771A), High dose formulation of HSV vaccine (GSK4108771A), Placebo (saline)
Biological · Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 40 Years
Enrollment
17 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
2
States / cities
Lenexa, Kansas • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 28, 2021 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

A Phase I/II Study of the Safety and Efficacy of Topical 1-(S)-(3-Hydroxy-2-Phosphonylmethoxypropyl)Cytosine Dihydrate (Cidofovir; HPMPC) in the Treatment of Refractory Mucocutaneous Herpes Simplex Disease in Patients With AIDS

NCT00002116
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Cidofovir
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
13 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • San Francisco, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 3 Interventional

A Study of Acyclovir to Help Prevent HIV Infection in People With Genital Herpes

NCT00076232
View directory record Official record
Conditions
HIV Infections, HIV Seronegativity, Herpes Genitalis
Interventions
Acyclovir, Acyclovir placebo
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
3,682 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
3
States / cities
San Francisco, California • New York, New York • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 30, 2010 · Synced Oct 5, 2026, 5:01 AM EDT
Completed No phase listed Observational

Seroprevalence of Kaposi's Sarcoma Herpes Virus in the United States

NCT00026728
View directory record Official record
Conditions
Kaposi's Sarcoma, Herpesviridae Infection
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
20,169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Study to Evaluate Efficacy, Safety and Immunogenicity of GSK Biologicals' Herpes Zoster (HZ) Vaccine GSK1437173A in Adults Aged 50 Years and Older

NCT01165177
View directory record Official record
Conditions
Herpes Zoster
Interventions
Herpes Zoster Vaccine GSK1437173A, Placebo
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
50 Years and older
Enrollment
16,165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
43
States / cities
Mesa, Arizona • Phoenix, Arizona • Tucson, Arizona + 36 more
Source: ClinicalTrials.gov public record
Updated Feb 10, 2021 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 1 Interventional

The Pilot Study of Foscarnet Cream in the Treatment of Mucocutaneous Herpes Simplex Virus Infections in Immunocompromised Patients Unresponsive to Acyclovir Treatment

NCT00002144
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Foscarnet sodium
Drug
Lead sponsor
Astra USA
Industry
Eligibility
13 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
8
States / cities
Los Angeles, California • Washington D.C., District of Columbia • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Not applicable Interventional

A Study to Compare the Efficacy and Safety of Valacyclovir Hydrochloride ( 256U87 ) Versus Acyclovir in the Treatment of Recurrent Anogenital Herpes Infections in HIV Infected Patients

NCT00002000
View directory record Official record
Conditions
Herpes Simplex, HIV Infections
Interventions
Valacyclovir hydrochloride, Acyclovir
Drug
Lead sponsor
Glaxo Wellcome
Industry
Eligibility
13 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
22
States / cities
Mobile, Alabama • San Francisco, California • Denver, Colorado + 17 more
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

VALTREX Once Daily For Viral Shedding In Herpes Simplex Virus 2 (HSV-2) Seropositive Subjects. VALTREX® Tablet is a Trademark of GlaxoSmithKline Group of Companies.

NCT00116844
View directory record Official record
Conditions
Infections, Herpesviridae
Interventions
Valaciclovir, Placebo
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2006
U.S. locations
17
States / cities
Carmichael, California • Davis, California • Riverside, California + 13 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare Sitavig (Acyclovir) Buccal Tablet With a Placebo in the Treatment of Herpes Labialis in Participants Whose Immune System Works Normally

NCT05098938
View directory record Official record
Conditions
Recurrent Herpes Labialis
Interventions
Acyclovir 50mg buccal/topical tablet, BAYM008894/UI1614773, Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
2,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Culver City, California
Source: ClinicalTrials.gov public record
Updated Sep 2, 2025 · Synced Oct 5, 2026, 5:01 AM EDT
Terminated Phase 4 Interventional Results available

Effect of HSV-2 Suppressive Therapy on Sexual Behavior

NCT00495716
View directory record Official record
Conditions
Genital Herpes
Interventions
acyclovir
Drug
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Mar 7, 2023 · Synced Oct 5, 2026, 5:01 AM EDT
Completed Phase 4 Interventional Results available

Zoster Eye Disease Study

NCT03134196
View directory record Official record
Conditions
Herpes Zoster Ophthalmicus
Interventions
Masked Placebo, Masked Oral Valacyclovir
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
71
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 58 more
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 5, 2026, 5:01 AM EDT